19:07 , Apr 27, 2018 |  BC Extra  |  Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates. The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2 billion...
19:08 , Apr 20, 2018 |  BC Week In Review  |  Company News

Advent to acquire Sanofi's EU generics business

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking to...
19:24 , Apr 17, 2018 |  BC Extra  |  Company News

Advent to acquire Sanofi's European generics unit for €1.9B

VC firm Advent International Corp. (Boston, Mass.) said it will acquire from Sanofi (Euronext:SAN; NYSE:SNY) the pharma's European generics business, Zentiva Group A/S, for €1.9 billion ($2.3 billion). Last year, Sanofi indicated it was looking...
08:00 , Nov 18, 2013 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks RBC Capital Marketsadded two managing directors: David Francis, who will cover healthcare IT and distribution services; and Randall Stanicky, who will lead the firm's specialty and generic pharmaceuticals research team. Francis founded research and...
07:00 , Sep 9, 2013 |  BioCentury  |  Finance

Banker tracks

Banker tracks Matthew McAskin joined Evercore Partnersas a senior managing director in the firm's healthcare investment banking group. McAskin was a managing director and co-head of healthcare services investment banking at Goldman Sachs. Buyside tracks Carl Harald Janson...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Grupo Farmaceutico Biotoscana S.A. deal

Toby Sykes, a principal at VC firm Essex Woodlands Health Ventures, said Essex and fellow VC firm Advent International acquired an undisclosed controlling stake in Biotoscana for an undisclosed sum at the end of 2011....
07:00 , Apr 18, 2011 |  BioCentury  |  Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from Dacogen...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Financial News

Nereus completes venture financing

Nereus Pharmaceuticals Inc., San Diego, Calif.   Business: Cancer, Infectious, Inflammation   Date completed: 6/22/10   Type: Venture financing   Raised: $20 million   Investors: HBM BioVentures; Alta Partners; Forward Ventures; Gimv N.V.; Advent International Corp.; Pacific Venture Group; ...
23:45 , Jun 22, 2010 |  BC Extra  |  Financial News

Nereus raises $20 million

Nereus Pharmaceuticals Inc. (San Diego, Calif.) raised $20 million in a private financing led by existing investor HBM BioVentures. Existing investors Alta Partners; Forward Ventures; Gimv; Advent International; Pacific Venture Group; Roche Venture Fund; and...
08:00 , Feb 22, 2010 |  BioCentury  |  Finance

Ebb & Flow

TVM Capitallast week announced a $40 million first close on a Middle East and North African-focused healthcare fund called TVM Capital MENA. Founding investors include Saudi Health Investment Co., the International Finance Corp. and GE...